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Global metabolic analyses identify 
key differences in metabolite levels 
between polymyxin-susceptible 
and polymyxin-resistant 
Acinetobacter baumannii
Mohd Hafidz Mahamad Maifiah1, Soon-Ee Cheah1, Matthew D. Johnson1, Mei-Ling Han1, 
John D. Boyce2, Visanu Thamlikitkul3, Alan Forrest4, Keith S. Kaye5, Paul Hertzog6,7, 
Anthony W. Purcell8, Jiangning Song8, Tony Velkov1, Darren J. Creek1,* & Jian Li1,*
Multidrug-resistant Acinetobacter baumannii presents a global medical crisis and polymyxins are 
used as the last-line therapy. This study aimed to identify metabolic differences between polymyxin-
susceptible and polymyxin-resistant A. baumannii using untargeted metabolomics. The metabolome of 
each A. baumannii strain was measured using liquid chromatography-mass spectrometry. Multivariate 
and univariate statistics and pathway analyses were employed to elucidate metabolic differences 
between the polymyxin-susceptible and -resistant A. baumannii strains. Significant differences were 
identified between the metabolic profiles of the polymyxin-susceptible and -resistant A. baumannii 
strains. The lipopolysaccharide (LPS) deficient, polymyxin-resistant 19606R showed perturbation in 
specific amino acid and carbohydrate metabolites, particularly pentose phosphate pathway (PPP) 
and tricarboxylic acid (TCA) cycle intermediates. Levels of nucleotides were lower in the LPS-deficient 
19606R. Furthermore, 19606R exhibited a shift in its glycerophospholipid profile towards increased 
abundance of short-chain lipids compared to the parent polymyxin-susceptible ATCC 19606. In contrast, 
in a pair of clinical isolates 03–149.1 (polymyxin-susceptible) and 03–149.2 (polymyxin-resistant, 
due to modification of lipid A), minor metabolic differences were identified. Notably, peptidoglycan 
biosynthesis metabolites were significantly depleted in both of the aforementioned polymyxin-
resistant strains. This is the first comparative untargeted metabolomics study to show substantial 
differences in the metabolic profiles of the polymyxin-susceptible and -resistant A. baumannii.
Acinetobacter baumannii is a Gram-negative, aerobic bacterium and a major cause of nosocomial infections 
worldwide, particularly in critically-ill patients1. A. baumannii infections include hospital-acquired pneumo-
nia, bloodstream infection, urinary tract infection, skin and soft tissue infections2,3. A. baumannii has become a 
significant global threat and is one of the six ‘superbugs’ identified by the Infectious Diseases Society of America 
(IDSA) which required urgent attention for discovery of novel antibiotics4. Recently, the United States Centers for 
Disease Control and Prevention (CDC) classified multi-drug resistant (MDR) A. baumannii as a microorganism 
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with a threat level of “Serious”5. A. baumannii has been characterised as ‘naturally transformable’, since it can 
rapidly acquire diverse resistance mechanisms and undergo genetic modifications that confer resistance to all 
current clinically used antibiotics1,2,6.
The clinical use of polymyxins waned in the 1970s due to potential nephrotoxicity and neurotoxicity7,8. 
However, over the last decade colistin (polymyxin E) and polymyxin B have been widely used as the only effec-
tive therapeutic option for patients infected with MDR A. baumannii9–11. Polymyxins are amphipathic, cationic 
lipopeptides that contain five L-α , γ -diaminobutyric acid (Dab) residues7,8. The bactericidal activity of poly-
myxins is exerted via the ‘self-promoted uptake’ pathway, initiated by electrostatic interaction with the lipid A 
of lipopolysaccharide (LPS) on the outer leaflet of the bacterial outer membrane7,12. In addition, a recent study 
suggested that polymyxins exert bacterial killing through a specific mechanism via the formation of hydroxyl 
radicals13. Polymyxin resistance in A. baumannii can be acquired via the addition of phosphoethanolamine14,15 
or galactosamine16 to lipid A structure. Our group firstly reported that A. baumannii ATCC 19606 spontaneously 
acquired colistin resistance following exposure to high levels of colistin, via the loss of its initial target, LPS17. 
Further analyses revealed LPS loss was due to single random mutations in the lipid A biosynthesis genes, lpxA, 
lpxC and lpxD17. Moreover, transcriptomic analyses of the A. baumannii LPS-deficient strain 19606R revealed 
significant up-regulation of genes involved in the cell envelope and membrane biogenesis, in particular of the Lol 
lipoprotein transport system and the Mla-retrograde phospholipid transport system18. We therefore hypothesised 
that the LPS-deficient strain 19606R exhibits significant changes in its metabolic profile in response to LPS loss. 
For bacteria, metabolomics is a powerful systems biology tool for understanding cell physiology and can com-
plement and validate data from genomics, transcriptomics and proteomics19–21. In this study, we report the first 
comparative untargeted metabolomics analyses of paired polymyxin-susceptible and polymyxin-resistant (via 
LPS loss or lipid A modifications) A. baumannii strains.
Results
Comparative untargeted metabolomics was employed to identify differences in the metabolic profile between 
polymyxin-susceptible and polymyxin-resistant A. baumannii strains. Two pairs of A. baumannii strains 
were examined: a laboratory-derived polymyxin-resistant, LPS-deficient lpxA-mutant strain, 19606R and its 
polymyxin-susceptible parent strain, ATCC 19606; and two clinical isolates, polymyxin-susceptible 03–149.1 
and polymyxin-resistant 03–149.2 obtained from a patient before and after colistin treatment, respectively. The 
polymyxin-resistant strain 19606R displayed a slower growth rate compared to the parent strain ATCC 19606, 
as previously reported17. Whereas, there was no significant difference in the growth rate between the paired 
polymyxin-susceptible 03–149.1 and polymyxin-resistant 03–149.2 clinical isolates.
Genomics and lipid A structural analysis of A. baumannii clinical isolates 03–149.1 
and 03–149.2. The paired A. baumannii clinical isolates of polymyxin-susceptible 03–149.1 and 
polymyxin-resistant 03–149.2 strains were initially identified using 16S rDNA gene sequencing; and showed 
96.17% and 97.15% sequence similarity to the A. baumannii ATCC 19606, respectively (Supplementary 
Table S1). Furthermore, a comparison of the polymyxin-susceptible 03–149.1 and the polymyxin-resistant 
03–149.2 by high-throughput sequencing and variant calling revealed 3 variations unique to the 03–149.2 iso-
late (Supplementary Table S2). One variation found in 03–149.2 was a deletion of 3 bases in the pmrB gene, 
which conferred an in-frame deletion of alanine 28. We also investigated the mechanism(s) of polymyxin 
resistance in the clinical isolate 03–149.2 with lipid A structural analysis. Lipid A samples isolated from both 
polymyxin-susceptible 03–149.1 and polymyxin-resistant 03–149.2 were characterised with electrospray ioni-
zation (ESI) high-resolution mass spectrometry in the negative-ion mode (Fig. 1). The mass spectrum of lipid 
A from the polymyxin-susceptible 03–149.1 shows a predominant peak at m/z 1911.28, which represents a 
hepta-acylated lipid A with four primary fatty acyls (i.e. two 3-hydroxylaurate [C12 (3-OH)] acyl chains and two 
3-hydroxymyristate [C14 (3-OH)] acyl chains), and three secondary fatty acyls (i.e. one C12 (3-OH) acyl chain and 
two laurate (C12) acyl chains); while the peak at m/z 1933.26 represents the sodium adduct of the hepta-acylated 
lipid A mentioned above (Fig. 1A). The peak at m/z 1883.25 is for a hepta-acylated lipid A with four primary C14 
(3-OH) acyl chains and three secondary fatty acyls (i.e. one C12 acyl chain, one C12 (3-OH) acyl chain, and one 
myristate (C14) acyl chain). The peak at m/z 1729.12 corresponds to a hexa-acylated lipid A, indicating the loss 
of a laurate acyl chain from the hepta-acylated lipid A at m/z 1911.28 (Δm/z = − 182). Additional peaks at m/z 
1649.15, 1803.29, 1831.32 differ from the peaks listed above by dephosphorylation at the 1 or 4′ position of lipid A 
(Δm/z = − 80), while the peaks at m/z 1712.12, 1867.26, and 1895.29 were only different from the corresponding 
peaks at m/z 1729.12, 1883.25, and 1911.28 by the mass of one oxygen atom (Δm/z = − 16), indicating the absence 
of 3-hydroxylation at the secondary laurate acyl chain.
Mass spectrometry analyses of lipid A from the polymyxin-resistant 03–149.2 isolate revealed several different 
types of modifications in the lipid A structure (Fig. 1B). The predominant peak at m/z 2034.29 represents the 
hepta-acylated lipid A at m/z 1911.28 modified with a phosphoethanolamine (pEtN) residue (Δm/z = + 123), 
while the peak at m/z 1954.32 indicates its dephosphorylated form (Δm/z = − 80). Minor peaks at m/z 1990.26, 
2006.26, and 2018.29 correspond to lipid A at m/z 1867.26, 1883.25, and 1895.29 which were modified with a 
pEtN group, respectively. The peak at m/z 2157.30 represents a modified lipid A with the addition of two pEtN 
moieties to the parent structure at m/z 1911.28. Interestingly, lipid A modified with galactosamine (GalN) was 
also detected in polymyxin-resistant 03–149.2. In detail, the peaks at m/z 2078.25 and 2094.33 represent lipid A 
at m/z 1895.29 and 1911.28 modified with a GalN residue (Δm/z = + 161) along with a sodium adduct, respec-
tively, and the peak at m/z 2195.36 corresponds to a lipid A (m/z 1911.28) with both pEtN and GalN additions 
(Δm/z = + 284) (Fig. 1B).
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Optimal metabolite recovery of MDR A. baumannii by washing with 0.9% NaCl and extraction 
using chloroform:methanol:water (1:3:1). Optimisation of the metabolite sampling method was per-
formed prior to the metabolomics analysis of paired polymyxin-susceptible and polymyxin-resistant strains. The 
potential for metabolite leakage during the washing step was examined by comparing washed and unwashed 
cell extracts, and analysing the washing waste supernatant. The hierarchical clustered heat map demonstrated 
that the washing step with 0.9% NaCl successfully removed the majority of culture media components (Fig. 2A). 
Recovery of intracellular metabolites (those not present in the broth) was not substantially impacted by washing. 
Analysis of the supernatant from the washing waste detected leakage of certain cell-derived metabolites, but at 
very low levels relative to the levels within the cell pellets. Furthermore, evaluation of four extraction solvents 
showed a total of 1099, 1104, 1070 and 1089 metabolites detected from the LC-MS analyses of metabolite sam-
ples extracted by the chloroform:methanol (CM; 1:2, v/v), chloroform:methanol:water (CMW; 1:3:1, v/v), 60% 
ethanol (60EtOH) and absolute methanol (MeOH) solvents, respectively. CMW was the most promising solvent, 
demonstrating efficient extraction of a wide range of metabolite classes (Fig. 2B). In addition, the median rela-
tive standard deviation (RSD) for all metabolites in the CMW samples was 22%, which is within an acceptable 
range and is comparable to the standard MeOH extraction solvent (Table 1). In comparison, CM and 60EtOH 
extraction solvents showed median RSD values of 25% and 24%, respectively. Peak intensities and RSD values for 
a number of common metabolites are provided in Table 1, showing that CMW was the most reproducible com-
pared to the other three extraction solvents.
Figure 1. The mass spectra of lipid A isolated from the A. baumannii clinical isolates. (A) Polymyxin-
susceptible 03–149.1 without lipid A modification. (B) Polymyxin-resistant 03–149.2 with lipid A modifications 
with phosphoethanolamine (pEtN) and galactosamine (GalN).
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Multivariate and univariate metabolomics analyses were able to identify key differences 
between the polymyxin-susceptible and polymyxin-resistant A. baumannii strains. The metab-
olomics data from the present LCMS-based comparative untargeted metabolomics study were highly reproduc-
ible. The pooled quality control samples clustered tightly in the PCA plot, indicating small analytical variations 
among the samples (Supplementary Figure S1). Furthermore, the median RSD value for all metabolites in this 
study was less than 10%. Global metabolome differences between four A. baumannii strains were visualised 
using PCA score plots (Fig. 3A) and heat map profiles (Fig. 4), and demonstrate that the polymyxin-resistant 
and polymyxin-susceptible strains differed significantly in their levels of a number of key cellular metabolites. 
PCA score plots also clearly show that there were global metabolic differences between the paired A. bauman-
nii strains (Fig. 3B,C). Interestingly, nearly 25% of metabolites in the LPS-deficient polymyxin-resistant strain 
19606R, were significantly more abundant than the corresponding polymyxin-susceptible parent strain ATCC 
19606 (Fig. 3D). Peptides were highly enriched in 19606R, and it appears that many of the more abundant metab-
olites in this polymyxin-resistant strain 19606R were derived from the growth medium (Fig. 4). The accumula-
tion of medium components within cells was unique to the LPS-deficient 19606R, and was not apparent in the 
polymyxin-resistant clinical isolate 03–149.2.
For univariate analyses, all the putatively identified cellular metabolites (i.e. those more abundant in cell 
pellets than in footprint samples) were further analysed to reveal those that showed at least 2-fold differences 
(*p < 0.05 and **p < 0.01) in relative abundance between the polymyxin-resistant and polymyxin-susceptible A. 
baumannii strains. Several cellular metabolites were differentially abundant in the polymyxin-susceptible ATCC 
19606 and polymyxin-resistant 19606R strains including carbohydrate, amino acid, nucleotide and lipid metabo-
lites. In comparison, there were very few metabolic differences observed in the polymyxin-resistant clinical isolate 
03–149.2 and polymyxin-susceptible clinical isolate 03–149.1 (Fig. 3D).
Perturbations in sugar and nucleotide metabolism. The polymyxin-resistant strain 19606R showed 
significant pertubations of several putative sugar phosphate metabolites, including metabolites associated with 
the pentose phosphate pathway (PPP). In particular, over 2-fold (p < 0.01) higher levels were observed for 
two PPP metabolites, D-erythrose 4-phosphate and D-sedoheptulose 7-phosphate, whereas the PPP-derived 
nucleotide precursor, 5-phospho-α -D-ribose 1-diphosphate (PRPP) was more than 3-fold (p < 0.01) lower 
than the polymyxin-susceptible parent strain ATCC 19606 (Fig. 5). On the contrary, the polymyxin-resistant 
clinical isolate 03–149.2 showed significantly lower abundance of the detected PPP metabolites, D-erythrose 
4-phosphate, D-sedoheptulose 7-phosphate, D-glyceraldehyde 3-phosphate, and D-ribose 5-phosphate 
Figure 2. Evaluation of washing step and extraction solvents in the sample pre-treatment method. 
(A) Clustered heat map distinguished the total metabolite recovery between cells subjected to washing 
with 0.9% NaCl and without washing. (B) Comparison of four different extraction solvents on the global 
metabolite recovery in A. baumannii: 60% ethanol, absolute methanol, chloroform:methanol (1:2, v/v), and 
chloroform:methanol:water (1:3:1, v/v).
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(p < 0.05) than the paired susceptible isolate 03–149.1. Besides, the levels of most nucleotides were significantly 
lower in the polymyxin-resistant 19606R than the parent polymyxin-susceptible ATCC 19606 strain (Fig. 6). 
However, there were no clear differences in nucleotide levels between the paired clinical isolates. Furthermore, 
two essential tricarboxylic acid (TCA) cycle intermediates, 2-oxoglutarate and cis-aconitate were identified at 
least 2-fold (p < 0.05) lower in relative abundance in the polymyxin-resistant 19606R cells (Fig. 7). Other TCA 
cycle metabolites, acetyl-CoA, citrate, and succinate, showed a consistent pattern of lower relative abundance in 
the polymyxin-resistant strain 19606R, albeit with less than two-fold difference. Interestingly, a similar pattern 
of metabolic changes were observed in the polymyxin-resistant clinical isolate 03–149.2; which showed lower 
abundance of citrate, cis-aconitate, 2-oxoglutarate and succinate than the polymyxin-susceptible clinical isolate 
03–149.1.
Variations of amino acid related metabolites in the polymyxin-resistant 19606R. The abun-
dance of several metabolites involved in phenylalanine, tyrosine, tryptophan and histidine metabolic pathways 
were significantly (p < 0.01) perturbed in the polymyxin-resistant 19606R strain (Table 2). Most notably, two 
putative metabolites associated with the shikimate pathway, shikimate-3-phosphate and 5-O-(1-Carboxyvinyl)-
3-phosphoshikimate were significantly higher in abundance (between 11- to 14-fold) in the polymyxin-resistant 
19606R compared to the polymyxin-susceptible parent strain ATCC 19606. Significant depletion was 
observed in three important peptidoglycan biosynthesis intermediates, N-succinyl-L,L-2,6-diaminopimelate, 
meso-diaminopimelate and UDP-N-acetylmuramoyl-L-alanyl-γ − D-glutamyl-meso-2,6-diaminopimelate which 
were 2- to 5-fold lower in the polymyxin-resistant 19606R (Fig. 8A). In addition, levels of these metabolites 
also decreased in the clinical polymyxin-resistant strain, 03–149.2. Interestingly, choline was undetectable in the 
polymyxin-resistant 19606R strain (Fig. 8B), suggesting differential uptake or utilisation of this metabolite from 
the growth medium. Footprint analysis revealed complete depletion of choline from the growth medium for the 
polymyxin-resitant 19606R, but not for the polymyxin-susceptible ATCC 19606 or both of the clinical isolates.
Perturbation of lipids levels in the LPS-deficient polymyxin-resistant 19606R. Analyses of 
cellular lipid metabolites in the polymyxin-resistant 19606R and polymyxin-susceptible ATCC 19606 revealed 
profound alteration (p < 0.05) of several putatively identified lipid metabolites. The observed accurate masses 
CM CMW 60EtOH MeOH
Median RSD value (%) 25 22 24 20
Identified compound
Amino acids 
 L-Lysine 4.1 × 10 7 (20.7) 5.7 × 107 (16.1) 4.1 × 107 (20.4) 4.2 × 107 (27.6)
 L-Serine 1.7 × 107 (22.2) 1.7 × 107 (13.7) 1.3 × 107 (15.7) 1.8 × 107 (7.3)
 L-Tyrosine 9.7 × 107 (14.0) 9.5 × 107 (12.8) 5.6 × 107 (17.6) 1.1 × 108 (11.2)
 L-Methionine 1.8 × 108 (11.9) 1.7 × 108 (13.9) 1.2 × 108 (14.5) 1.9 × 108 (10.4)
 L-Phenylalanine 3.0 × 108 (13.4) 2.7 × 108 (13.0) 1.8 × 108 (10.8) 2.7 × 108 (9.5)
 L-Valine 1.0 × 107 (14.1) 9.6 × 106 (10.2) 7.4 × 106 (13.7) 1.0 × 107 (5.6)
 L-Aspartate 2.8 × 107 (11.8) 2.5 × 107 (9.4) 2.2 × 107 (10.5) 2.6 × 107 (6.3)
Energy
 NADPH 5.4 × 105 (45.0) 1.6 × 106 (11.5) 3.8 × 105 (48.3) 6.9 × 105 (35.1)
 NAD+ 4.6 × 107 (33.0) 7.6 × 107 (9.8) 3.4 × 107 (16.1) 5.5 × 107 (23.4)
FMN 4.7 × 105 (31.3) 6.2 × 105 (7.6) NA* 4.0 × 105 (61.7)
Nucleotides
 Adenine 6.7 × 106 (46.7) 5.1 × 106 (15.6) 2.3 × 106 (41.8) 8.8 × 106 (26.6)
 Cytidine 9.1 × 106 (24.1) 8.7 × 106 (11.9) 4.0 × 106 (10.9) 8.1 × 106 (10.1)
 Guanine 2.1 × 105 (38.6) 2.1 × 105 (12.6) 1.5 × 105 (28.2) 2.5 × 105 (12.9)
 Uridine 8.7 × 106 (19.2) 8.2 × 106 (14.0) 5.0 × 106 (15.2) 1.0 × 107 (17.3)
Carbohydrate
 Pyruvate 3.0 × 105 (19.8) 3.0 × 105 (17.0) 2.4 × 105 (25.2) 2.8 × 105 (10.7)
 Sucrose 2.0 × 106 (39.2) 1.9 × 106 (13.5) 1.1 × 106 (13.7) 1.8 × 106 (14.7)
 Citrate 1.7 × 107 (38.7) 2.8 × 107 (14.9) 2.7 × 107 (20.4) 2.2 × 107 (18.6)
 cis-Aconitate 2.3 × 105 (29.3) 4.5 × 105 (14.9) 2.6 × 105 (17.8) 3.3 × 105 (19.5)
 Oxalate 2.5 × 105 (22.7) 2.7 × 105 (19.3) 2.8 × 105 (29.2) 2.3 × 105 (22.9)
 (R,R)-Tartaric acid 3.2 × 104 (19.4) 4.0 × 104 (17.3) 3.4 × 104 (23.3) 3.3 × 104 (22.3)
Table 1.  Validation and reproducibility of metabolite extraction procedure for four different extraction 
solvents. CM, chloroform:methanol (1:2, v/v); CMW, chloroform:methanol:water (1:3:1, v/v); 60EtOH, 60% 
ethanol; MeOH, absolute methanol (3 biological samples with 3 technical replicates per condition). *NA, not 
available as the metabolite was not detected. Data are expressed as mean relative intensity (relative standard 
deviation, RSD, %).
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and retention times indicated that many of these lipids were unsaturated and oxidised fatty acids; precise iden-
tification of these fatty acids is beyond the scope of this study. High level identification of glycerophospholipids 
(GPs) based on molecular formula revealed signficant perturbations in the major phospholipid species, glycero-
phosphoethanolamine (PE), glycerophosphoserine (PS), and glycerophosphoglycerol (PG). In general, GPs with 
shorter-chain fatty acids (total ≤ 32 carbons) were enriched in the polymyxin-resistant LPS-deficient 19606R, 
in addition to the shorter-chain lysophospholipids (≤ 18 carbons) (Fig. 9A). Notably, lipids with longer-chain 
fatty acids (> 32 carbons) were generally depleted in the LPS-deficient 19606R. However, these trends were not 
observed in A. baumannii of both clinical isolates, polymyxin-susceptible 03–149.1 and polymyxin-resistant 
03–149.2 (Fig. 9B). Furthermore, two key metabolites linked with glycerophospholipid metabolism, ethanol-
amine phosphate and glyceroethanolamine phosphate were significantly (p < 0.05) lower in abundance in the 
Figure 3. (A) PCA score plot of four A. baumannii strains. (B) PCA score plot of paired polymyxin-resistant 
19606R and the wild-type ATCC 19606. (C) PCA score plot of paired polymyxin-resistant 03–149.2 and 
polymyxin-susceptible 03–149.1 clinical isolates. Each data set for individual strains represents a total of 
12 sample replicates (3 biological replicates and each with 4 technical replicates). (D) Pathway-focused 
representation of the significant metabolites (black bars) and total number of putatively identified metabolites 
(open bars) for the polymyxin-resistant 19606R relative to the wild-type ATCC 19606 (left) and the polymyxin-
resistant clinical isolate 03–149.2 relative to the polymyxin-susceptible isolate 03–149.1 (right). Significant 
metabolites were selected by at least 2-fold difference (p < 0.05) in the metabolites levels of polymyxin-resistant 
strain relative to the polymyxin-susceptible strain.
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polymyxin-resistant 19606R than the polymyxin-susceptible parent strain ATCC 19606, but not significantly 
changed in both A. baumannii clinical isolates (Fig. 9C).
Untargeted analysis reveals unknown metabolites that are common to both polymyxin- 
resistant strains. Four unidentified features were uniquely detected in both polymyxin-resistant strains 
and not in either of the polymyxin-susceptible strains. Whilst these features could not be identified based on 
existing bacterial metabolite databases, formula determination based on accurate mass, isotope abundance 
and retention time suggests that these unique metabolites may be complex amino-sugars: C12H24N2O8 (mass 
324.153; tR 14.7 min), C30H57N2O12P3 (mass 730.312; tR 17.2 min), C13H26N2O6 (mass 306.179; tR 19.8 min), and 
C16H28N2O11[Cl-] (mass 460.146; tR 13.7 min). Notably, three unidentified metabolites were detected in both 
polymyxin-susceptible strains, but were absent in both of the polymyxin-resistant strains. Accurate mass indi-
cates that these features likely represent metabolites with the formulas C9H14N2O5S (mass 262.063; tR 13.4 min), 
Figure 4. Heat map profiles of metabolite peak intensities in A. baumannii. Left: paired strains of ATCC 
19606 and polymyxin-resistant 19606R, Right: paired clinical isolates polymyxin-susceptible 03–149.1 and 
polymyxin-resistant 03–149.2. Metabolites are grouped into different classes: amino acids, carbohydrates, 
energy, lipids, nucleotides, peptides and undefined. Metabolites derived from the footprint (fp) also represented 
in the heat map. The colors indicate the relative abundance of metabolites based on the relative peak intensity 
(red = high, yellow = no change, blue = undetectable).
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C7H11NO3S (mass 189.046; tR 7.5 min) and C11H19N3O7S2 (mass 369.066, tR 16.8 min). The latter formula cor-
responds to γ -glutamyl cystine, and the presence of sulfur in the other formulas suggest that they may also be 
cysteine conjugates.
Discussion
In recent times, untargeted metabolomics has been successfully applied towards the investigation of global met-
abolic profiles, particularly in microbiology and pharmacology22–24. Advantageously, the untargeted metabolo-
mics platform enables the detection of both known and unknown metabolites and has allowed the elucidation 
of complex interactions between cellular metabolites21. Significantly, this global metabolomics approach has 
been beneficial in enhancing our understanding of the biological nature of antimicrobial resistance mechanisms. 
Global metabolic profiling distinguished differential metabolic patterns between antibiotic-susceptible and 
antibiotic-resistant strains of A. baumannii, Pseudomonas aeruginosa, Nocardiopsis spp., as well as the protozoan 
parasites Trypanosoma brucei and Leishmania donovani25–29. In a previous study, both planktonic and biofilm 
forms of A. baumannii were compared to identify metabolic profiles associated with biofilm synthesis25. In the 
present study, we employed a global metabolic profiling strategy to identify key metabolic differences between 
two pairs of polymyxin-susceptible and polymyxin-resistant A. baumannii strains, specifically conferred by two 
different mechanisms of polymyxin resistance, LPS loss and lipid A modifications.
Gram-negative bacteria can develop resistance to most current antimicrobial agents because of their extraor-
dinary metabolic versatility and adaptability to a wide range of environmental conditions2. The main mecha-
nisms used for conferring polymyxin resistance in Gram-negative bacteria involved modifications of lipid A, 
the membrane embedded component of lipopolysaccharides (LPS)7. In a previous study, we discovered that A. 
baumannii can develop resistance to very high colistin concentrations through a complete loss of LPS, due to 
spontaneous mutations in any one of the three key lipid A biosynthetic genes17. Polymyxin resistance in 19606R 
was shown to be conferred by a spontaneous single mutation in lpxA gene, resulting in LPS loss17. RNA expression 
profiling of polymyxin-resistant 19606R by our group indicated that significant outer-membrane remodelling 
Figure 5. Pertubations of identified sugar phosphates in A. baumannii. Pentose phosphate pathway 
(PPP) of A. baumannii. PPP intermediates showed significant differences between polymyxin-resistant and 
polymyxin-susceptible A. baumannii strains. Metabolites in the red bold box indicate metabolites that were 
at least 2-fold more abundant in polymyxin-resistant 16906R strain than polymyxin-susceptible ATCC 19606 
strain. Metabolites in the red box indicate metabolites that were less than 2-fold more abundant in the 19606R 
strain. The blue bold box indicates the metabolite that was at least 2-fold less abundant in 16906R than ATCC 
19606. The blue box indicates the metabolite that was less than 2-fold less abundant in the 03–149.2 polymyxin-
resistant strain than polymyxin-susceptible 03–149.1 strain. The black boxes indicate metabolites that were not 
detected. *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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occurs due to LPS loss18. This included increased expression of genes involved in cell envelope and membrane 
biogenesis, in particular the Lol lipoprotein transport system, the Mla-retrograde phospholipid transport system 
and poly-β -1,6-N-acetylglucosamine (PNAG) biosynthesis18. In addition, polymyxin-resistant 19606R displays 
a decreased expression of genes predicted to encode the fimbrial subunit FimA and components involved in the 
type VI secretion system (T6SS)18.
Our genome sequencing data for the polymyxin-resistant isolate 03–149.2 show that the deletion of 3 bases in 
the pmrB gene conferred an in-frame deletion of alanine 28. This particular mutation has not been characterized 
previously. However, mutations in pmrB have repeatedly been shown to cause polymyxin resistance in A. bauman-
nii by the upregulation of the phosphoethanolamine transferase, pmrC, and subsequent lipid A modification30. 
Furthermore, structural analyses of lipid A from both polymyxin-susceptible 03–149.1 and polymyxin-resistant 
03–149.2 clinical isolates revealed lipid A modifications with phosphoethanolamine (pEtN) and galactosamine 
(GalN) in the polymyxin-resistant 03–149.2 strain (Supplementary Figure S2). These lipid A modifications play 
a role in polymyxin resistance similar to that of aminoarabinose modification in other Gram-negative bacte-
ria31,32 which reduce the initial electrostatic interaction with polymyxins by reducing the negative charge on the 
bacterial outer membrane7,33,34. The results clearly indicate that the mechanism of polymyxin resistance in the 
polymyxin-resistant 03–149.2 isolate differs from the A. baumannii 19606R resistant strain, which was due to the 
complete loss of LPS17.
Careful assessment of sample preparation methods is an important pre-requisite step to generate physiological 
metabolome data based on the differences in cell composition and culture condition35. In our study, the effect of 
the washing step and the efficiency of four different extraction solvents were firstly examined. Since a very rich 
culture medium, cation-adjusted Mueller-Hinton broth (MHB) was used in this study, a washing process was 
essential to avoid medium effects and to ensure that detected metabolites solely derive from cells36. Desirably, 
the leakage of intracellular metabolites into its extracellular environment should be avoided during the washing 
step37. As washing with organic solvents at sub-zero temperature leads to the leakage of cellular metabolites38, 
we implemented a quenching step at 0 °C and washing in aqueous buffer 0.9% NaCl (4 °C). The washing process 
was effective in eliminating most of the extracellular contaminants from the rich growth media whilst avoid-
ing significant leakage of intracellular metabolites. Furthermore, the ideal extraction solvent should be able to 
extract a broad range of metabolites with different physicochemical properties in high and reproducible yield39. 
Several extraction solvents have been reported in the literature for bacterial metabolomics, and four promising 
solvent compositions were selected to determine the optimal extraction method specifically for A. baumannii in 
the present study. Unsurprisingly, our analyses showed that different extraction solvents preferentially extract 
certain metabolites depending on the polarity of the solvent. Overall, CMW (1:3:1, v/v) provided the greatest 
Figure 6. Heat map profiles of relative abundance of nucleotides. The polymyxin-resistant 19606R and its 
parent ATCC 19606 (left) and the clinical isolates polymyxin-resistant 03–149.2 and polymyxin-susceptible 
03–149.1 (right). The colors indicate the relative abundance of metabolites based on the relative peak intensity 
(red = high, yellow = no change, blue = undetectable).
www.nature.com/scientificreports/
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recovery and reproducibility for the largest number of different classes of metabolites, and is suitable to be used 
as a one-step method for untargeted metabolomics studies of A. baumannii.
Metabolic fingerprinting of two pairs of polymyxin-susceptible and polymyxin-resistant A. baumannii strains 
demonstrated accumulation or depletion of specific metabolite pools, indicating differential regulation of particu-
lar metabolic pathways. Interestingly, PCA plots clearly distinguished the metabolic profile differences between 
the polymyxin-resistant strain 19606R and the three other A. baumannii strains, signifying that the metabolic 
differences were substantially driven by the complete loss of outer membrane LPS. Notably, there were clear 
metabolic differences between the polymyxin-susceptible ATCC 19606 and polymyxin-resistant 19606R. In 
contrast, relatively very few metabolite differences were identified between the A. baumannii clinical isolates, 
polymyxin-susceptible 03–149.1 and polymyxin-resistant 03–149.2, demonstrating that lipid A modifications 
had minimal impact on the global metabolic profile. In general, the results show that different mechanisms of 
polymyxin resistance lead to unique changes in global metabolic profiles.
Our results demonstrate that peptides derived from the medium component were substantially accumu-
lated in the polymyxin-resistant strain 19606R compared to other A. baumannii strains, and suggested that the 
uptake was facilitated significantly as a result of loss membrane integrity from the total LPS loss. The analy-
ses of carbohydrate associated metabolites displayed higher levels of pentose phosphate pathway (PPP) inter-
mediates in the polymyxin-resistant 19606R than in its susceptible parent strain ATCC 19606. In contrast, 
the polymyxin-resistant 03–149.2 showed significantly lower levels of detected PPP-associated metabolites 
than the polymyxin-susceptible 03–149.1. However, a major end-product of the PPP, 5-phospho-α -D-ribose 
1-diphosphate (PRPP), was 3.5-fold lower in abundance in the polymyxin-resistant 19606R, suggesting diver-
sion of flux through the non-oxidative branch of the PPP. PRPP is an essential precursor for both purine and 
pyrimidine nucleotide biosynthesis as well as for the biosynthesis of amino acids histidine and tryptophan40. 
Coincidently, decreased levels of nucleotides was observed in 19606R, as well as depletion of two histidine 
metabolites, N-formimino-L-glutamate (24-fold) and urocanate (3-fold), which may be secondary to the 
Figure 7. Pertubations of TCA cycle intermediates in A. baumannii. TCA cycle of A. baumannii. The blue 
bold box indicates metabolites that were at least 2-fold less abundant in the polymyxin-resistant 19606R strain 
than polymyxin-susceptible ATCC 19606. Metabolites in the blue box indicate metabolites that were less than 
2-fold less abundant in 19606R than ATCC 19606. The green boxes indicate metabolites that were detected but 
not significant. The black boxes indicate metabolites that were not detected. *p < 0.05; **p < 0.01.
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decreased concentration of PRPP. However, the significant depletion of nucleotide levels was not observed in the 
polymyxin-resistant 03–149.2 clinical isolate. The increased level of D-erythrose 4-phosphate (2-fold) generated 
in the PPP of the polymyxin-resistant 19606R strain appears to facilitate biosynthesis of the aromatic amino 
acids: phenylalanine, tyrosine, and tryptophan through the shikimate pathway, as shown by the significant accu-
mulation of two intermediates, shikimate-3-phosphate (14-fold) and 5-O-(1-Carboxyvinyl)-3-phosphoshikimate 
(11-fold)41. Apart from the importance of PPP to conserve stable carbon equilibrium, to generate nucleotide 
and amino acid biosynthesis precursors and to supply reducing molecules for anabolism, PPP also has been 
found to be essential in the biosynthesis of LPS in Gram-negative bacteria42. SHI, an enzyme that has been char-
acterised in Escherichia coli, P. aeruginosa43 and Helicobacter pylori44 converts sedoheptulose 7-phosphate into 
the LPS precursor, glycero-manno-heptose 7-phosphate43,45,46. Interestingly, we identified that the level of this 
particular metabolite, D-sedoheptulose 7-phosphate was about 2-fold higher (**p < 0.01) than the other three 
A. baumannii strains. We hypothesised that, as the polymyxin-resistant 19606R is characterised by the total LPS 
loss17, the metabolite, sedoheptulose 7-phosphate was significantly accumulated in the cells since it was not con-
verted into the LPS precursor. The TCA cycle is another essential central metabolic pathway in bacterial cells, 
providing substrates for energy and biosynthetic reactions, including precursors for lipids and amino acids47. 
Notably, both polymyxin-resistant strains, 19606R and clinical isolate 03–149.2 showed lower abundance of 
TCA cycle metabolites than their respective polymyxin-susceptible strains. This suggested that, in general, the 
polymyxin-resistant strains produced less energy through TCA cycle indicating lower cellular metabolism than 
the polymyxin-susceptible strains and this was significantly observed particularly in the polymyxin-resistant 
strains, 19606R.
Three intracellular metabolites engaged in the peptidoglycan biosynthesis pathway, meso-diaminopimelate, 
UDP-N-acetylmuramoyl-L-alanyl-γ -D-glutamyl-meso-2-6-diaminopimelate, and N-succinyl-L,L-
2,6-diaminopimelate were detected 2- to 5-fold less abundant in the polymyxin-resistant 19606R strain, com-
pared to the parent strain ATCC 19606. Interestingly, these metabolites were also significantly decreased (2- to 
3-fold) in the polymyxin-resistant clinical isolate 03–149.2. Meso-diaminopimelate is derived from lysine deg-
radation and is conjugated with UDP-N-acetylmuramoyl-L-alanyl-D-glutamate (catalysed by MurE ligase) in 
the cytoplasm to form UDP-N-acetylmuramoyl-L-alanyl-γ -D-glutamyl-meso-2-6-diaminopimelate48. This is fol-
lowed by the addition of dipeptide D-alanyl-D-alanine to form UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-
6-carboxy-L-lysyl-D-alanyl-D-alanine (catalysed by MurF ligase). In E. coli, the MurE and MurF ligases are 
encoded by the murE and murF genes, respectively, co-localised in the genome; these ligases are essential for 
bacterial viability and are targets for antibacterial chemotherapy49. The lower levels of the peptidoglycan biosyn-
thesis metabolites indicate that the polymyxin-resistant 19606R and clinical isolate 03–149.2 synthesised less pep-
tidoglycan compared to their polymyxin-susceptible parent strains. Interestingly, choline levels were significantly 
depleted in the 19606R strain and its culture medium. In our recent transcriptomics study, the expression of 
choline dehydrogenase, choline-glycine betaine transporter and choline transport protein BetT was significantly 
increased (3.0, 3.0 and 4.6 folds, respectively) in the polymyxin-resistant A. baumannii 19606R18. As choline 
uptake and metabolism have been associated with maintenance of osmotic balance in Gram-negative bacteria45,50, 
our transcriptomics and metabolomics data collectively indicate that choline was required by 19606R in response 
Formula Putative metabolitea Pathway/metabolism
Fold 
change P-value
Carbohydrate 
 C5H12O5 Xylitol
Pentose and glucoronate 
interconversions 3.47 0.00017
 C12H23O14P Lactose 6-phosphate Galactose metabolism 2.14 0.0018
 C3H6O9P2 Cyclic 2,3-bisphospho-D-glycerate Carbohydrate metabolism – 3.01 0.0035
Amino acids 
 C7H11O8P Shikimate 3-phosphate
Phenylalanine, tyrosine, tryptophan 
biosynthesis 14.41 0.0012
 C10H13O10P 5-O-(1-Carboxyvinyl)-3-phosphoshikimate
Phenylalanine, tyrosine, tryptophan 
biosynthesis 11.30 0.0079
 C8H8O5 3,4-Dihydroxymandelate Tyrosine 3.03 0.00074
 C4H6O3 2-Methyl-3-oxopropanoate
Valine, leucine and isoleucine 
degradation 2.19 0.00060
 C2H5O5P Acetyl phosphate Taurine and hypotaurine 2.15 9.2E-05
 C9H8O3 Phenylpyruvate Phenylalanine – 2.00 5.9E-05
 C9H10O4 3-(2,3-Dihydroxyphenyl)propanoate Phenylalanine – 2.03 0.0011
 C13H15NO6 4-Hydroxyphenylacetylglutamic acid Tyrosine – 2.08 0.0077
 C7H15NO3 L-Carnitine Lysine degradation – 2.57 0.00049
 C6H6N2O2 Urocanate Histidine – 3.75 0.0031
 C6H10N2O4 N-Formimino-L-glutamate Histidine – 24.86 0.00095
Table 2.  Fold changes (relative intensity) in the abundance of metabolites detected in the LPS-deficient 
polymyxin-resistant 19606R, relative to the parent strain ATCC 19606. aPutative metabolites, identified by 
exact mass, with at least 2-fold differences at p value < 0.01 between the polymyxin-resistant 19606R and the 
polymyxin-susceptible ATCC 19606.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:22287 | DOI: 10.1038/srep22287
to the osmolarity pressure due to the less peptidoglycan caused by polymyxin resistance. However, there was no 
profound change in choline level in the polymyxin-resistant clinical isolate 03–149.2 proposing that choline was 
not utilised and the level was in equilibrium state between intracellular and extracellular.
The outer membrane (OM) of Gram-negative bacterial cells is composed of an asymmetrical bilayer con-
sisting of an outer leaflet with LPS as a major component, and the inner leaflet mainly containing glycerophos-
pholipids (GPs)51. The OM serves as an efficient permeability barrier and a first-line defence mechanism, and 
GPs are the most prevalent component of lipids in the bacteria OM52. Compared to GPs species in the samples 
obtained from ATCC 19606, the LPS-deficient, polymyxin-resistant 19606R produced relatively high levels of GP 
species PE, PS and PG with shorter fatty acyl chains (less than 32 carbons in both chains) and concomitantly less 
GP species with more than 34 carbons in their fatty acyl chains. This finding agrees with a previous report that 
showed a LPS-deficient Neisseria meningitides mutant preferentially incorporated saturated PE and PG species 
with shorter fatty acyl chains into its OM53. Furthermore, the higher abundance of lyso-GPs (those with a single 
fatty acid chain less than 18 carbons) in the polymyxin-resistant 19606R, compared to the parent strain ATCC 
19606, indicate significant GPs turnover; hence, our result supports the hypothesis that the OM structure of 
polymyxin-resistant bacterial cells is dramatically altered due to LPS loss. The observed increase in the produc-
tion of GPs, which we hypothesise are mainly exported to the outer leaflet of the OM of the LPS-deficient strain 
19606R, further supports the previously described the compensatory mechanism for the LPS loss which associ-
ated with increase in cell envelope and membrane biosynthesis18. Transcriptomics analyses of the LPS-deficient 
strain 19606R revealed that there was a significant increase in the expression of genes involved in phospholipid 
Figure 8. Levels of peptidoglycan biosynthesis metabolites and choline in A. baumannii. (A) Peptidoglycan 
synthesis pathway of A. baumannii. Metabolites in the red box indicate metabolites that were less than 2-fold 
higher in polymyxin-resistant strains than polymyxin-susceptible strains. The blue and bold boxes indicate 
metabolites that were at least 2-fold lower in polymyxin-resistant strains than polymyxin-susceptible strains. 
Metabolites in the blue box indicate less than 2-fold lower abundance in polymyxin-resistant strains than 
polymyxin-susceptible strains. The green box indicates metabolites that were detected but not significant. 
Metabolites in the black box were not detected. (B) Intracellular and footprint (extracellular) choline shows 
significantly lower abundance in the polymyxin-resistant 19606R than the parent wild-type ATCC 19606. 
*p < 0.05; **p < 0.01.
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transport (mlaBCD) in response to the LPS loss18. Remarkably, glyceroethanolamine phosphate and ethanol-
amine phosphate showed significantly lower levels in the polymyxin-resistant 19606R than its parent ATCC 
19606. Ethanolamine utilisation was suggested to associate with bacterial pathogenesis and virulence54,55. Our 
results support the claim and suggest that ethanolamine is crucial for bacterial metabolism, in particular in the 
polymyxin-resistant 19606R. The present study utilising HILIC chromatography does not represent the total 
phospholipid composition and does not reveal the relative distribution of each GP species in the inner and outer 
membranes of A. baumannii. Future membrane lipidomics analysis of LPS-deficient, polymyxin-resistant A. bau-
mannii is underway and will further define the total lipid abundance and distribution.
In addition to the perturbations to known metabolic pathways, our untargeted metabolomics analysis 
revealed four unidentified metabolite features which are consistent with amino-sugars that were unique to the 
polymyxin-resistant strains, and not in either of the polymyxin-susceptible strains. Metabolite identification is a 
Figure 9. Relative intensity of glycerophospholipids levels. (A) LPS-deficient polymyxin-resistant 19606R 
and its parent strain ATCC 19606; and (B) polymyxin-resistant 03–149.2 and polymyxin-susceptible 
03–149. (C) Glyceroethanolamine phosphate and ethanolamine phosphate showed significantly lower levels 
in the polymyxin-resistant 19606R than its parent ATCC 19606. PE, glycerophosphoethanolamine; PS, 
glycerophosphoserine; PG, glycerophosphoglycerols; PA, glycerophosphates. Fatty acyl carbon atom number 
and double bond number are shown in brackets. *p < 0.05.
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major bottleneck in untargeted metabolomics, and accurate identification of metabolites that are not present in 
existing databases requires large-scale fractionation and extensive structural analysis56–58. Precise structural iden-
tification of the unknown metabolites that are unique to polymyxin-resistant strains is beyond the scope of the 
present study. Nevertheless, with the high-resolution MS applied here, features can be annotated with the most 
likely molecular formulas. Whilst not conclusive, these unique unidentified metabolites suggest the involvement 
of glycan metabolism in the molecular mechanisms of polymyxin resistance in A. baumannii. Further studies are 
warranted to characterise these unknown metabolites and their biological functions. Together with our metab-
olomics and transcriptomics results18, it will provide additional information about the metabolic differences 
between polymyxin-susceptible and polymyxin-resistant A. baumannii (Figs 3 and 4).
To the best of our knowledge, this comparative untargeted metabolomics study is the first to demonstrate 
significant global metabolic changes in polymyxin-resistant A. baumannii strains. In particular, global metabolic 
differences are associated with different mechanisms of polymyxin resistance due to LPS loss and lipid A modi-
fications. Our study provides a valuable insight into the global metabolism of polymyxin-resistant A. baumannii 
and potentially offers new therapeutic targets.
Materials and Methods
Strains. The A. baumannii wild-type strain ATCC 19606 was obtained from the American Type Culture 
Collection. The lpxA mutant strain 19606R (MIC > 128 mg/L) is an LPS-deficient, polymyxin-resistant deriv-
ative of ATCC 1960617. The two clinical isolates used in this study were polymyxin-susceptible 03–149.1 (MIC 1 
mg/L) and polymyxin-resistant 03–149.2 (MIC > 32 mg/L); both were isolated from the same patient59. Bacterial 
strains were grown in cation-adjusted Mueller-Hinton broth (MHB; Oxoid, England; 20–25 mg/L Ca2+ and 
10–12.5 mg/L Mg2+).
Identification of 16S rDNA, genome sequencing and lipid A structural analysis of A. baumannii 
clinical isolates 03–149.1 and 03–149.2. The A. baumannii clinical isolates 03–149.1 and 03–149.2 16S 
were identified using rDNA gene sequencing (Supplementary Method). Their genome sequences were deter-
mined using 36-bp paired-end sequencing chemistry on an Illumina Genome Analyzer II apparatuse (Illumina) 
at the Micromon Sequencing Facility (Monash University) as previously described17. Furthermore, lipid A of the 
clinical isolates 03–149.1 and 03–149.2 was prepared by mild acid hydrolysis as previously described60. In detail, 
100 mL of broth cultures were harvested at OD600nm = 0.8 via centrifugation at 3,220 × g for 20 min and washed 
twice with phosphate-buffered saline (PBS). Initially, the cells were re-suspended in 4 mL PBS, methanol (10 mL) 
and chloroform (5 mL) were then added to the suspension, making a single-phase Bligh-Dyer (chloroform/meth-
anol/water, 1:2:0.8, v/v)61. The mixture was centrifuged at 3,220 × g for 15 min and supernatant was removed. The 
pellet was washed once with chloroform/methanol/water (1:2:0.8, v/v), re-suspended in the hydrolysis buffer 
(50 mM sodium acetate pH 4.5, 1% sodium dodecyl sulphate (SDS)), and incubated in a boiling water bath for 
45 min. To extract lipid A, the SDS solution was converted into a double-phase Bligh-Dyer mixture by adding 
6 mL of chloroform and 6 mL of methanol for a final mixture of chloroform/methanol/water (1:1:0.9, v/v)61. The 
lower phase containing lipid A was finally extracted and samples were dried and stored at – 20 °C. Structural anal-
ysis of lipid A was performed in negative mode on a Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer 
(Thermo Fisher).
Bacterial culture preparation for metabolomics experiments. Bacterial strains, subcultured 
from – 80 °C frozen stocks, were inoculated onto nutrient agars and incubated for 16–18 h at 37 °C. For the 
polymyxin-resistant strains, lpxA mutant 19606R and clinical isolate 03–149.2, the Mueller-Hinton plates were 
supplemented with polymyxin B (10 mg/L) to maintain the selection pressure. For each culture, a single colony 
was used to inoculate 10 mL MHB for incubation overnight (16–18 h) at 37 °C with constant shaking (180 rpm). 
Three biological replicate reservoirs for different A. baumannii colonies, each consisting of 50 mL MHB, were 
prepared for each A. baumannii strain. Each reservoir was inoculated with 500 μL of overnight culture and grown 
at 37 °C with shaking (180 rpm) to an OD600nm ~0.5 (mid-exponential growth phase). The polymyxin-resistant 
strains 19606R and 03–149.2 were grown in MHB without colistin. For the blank controls, two MHB reservoirs 
without bacterial inoculation were included in the experiment.
Sample preparation for metabolomic study. Metabolomic sample was prepared as previously 
described with slight modifications36. The sample pre-treatment method, washing step and extraction solvents 
were optimised for improved recovery of cellular metabolites. The final method for cell pellet analyses employed 
four technical replicates, each consisting of 10 mL mid-exponential culture (OD600nm ~0.5) collected in 50 mL 
Falcon tubes (Thermo Fisher). The tubes were centrifuged at 3,220 × g at 4 °C for 5 min and the supernatant dis-
carded. For each sample, extracellular metabolites and medium components were removed by washing cell pellets 
twice with 0.5 mL of 0.9% NaCl (4 °C). Following each wash, cells were pelleted by centrifugation at 3,220 × g at 
4 °C for 3 min. To evaluate the washing effect on the metabolite leakage, washing waste supernatant samples were 
collected and analysed (below). Furthermore, the efficiency of four different extraction solvents were evaluated: 
(i) absolute methanol (MeOH), (ii) 60% ethanol (60EtOH), (iii) chloroform:methanol:water (CMW; 1:3:1, v/v), 
and (iv) chloroform:methanol (CM; 1:2, v/v). In our comparison study of different A. baumannii strains, washed 
cell pellets were resuspended in 0.5 mL metabolite extraction solvent consisting of CMW (1:3:1, v/v; − 80 °C); the 
solvent mixture contained the internal standards (CHAPS, CAPS, PIPES and TRIS; 1 μM of each). These com-
pounds were selected as the internal standards as they are physicochemically diverse small molecules that are not 
naturally occurring in any microorganism and can be spiked at known concentrations to determine the analytical 
performance of the method used. Samples were frozen in liquid nitrogen and thawed on ice, and freeze-thaw was 
repeated three times in order to permeabilise the cells and release intracellular metabolites. The mixtures were 
www.nature.com/scientificreports/
1 5Scientific RepoRts | 6:22287 | DOI: 10.1038/srep22287
centrifuged for 10 min at 3,220 × g at 4 °C and 300 μL of the supernatants containing the extracted metabolites 
were collected in 1.5-mL centrifuge tubes and stored at – 80 °C immediately. For analysis, the samples were thawed 
and further centrifuged at 14,000 × g for 10 min at 4 °C and 200 μL of particle-free supernatant was transferred 
into the injection vial for LC-MS analysis. For footprint samples, an aliquot of approximately 1.5 mL of the culture 
was rapidly filtered through a 0.22-μm filter and stored at – 80 °C. Prior to analysis, these samples were thawed and 
10 μL combined with 250 μL extraction solvent (chloroform:methanol:water, 1:3:1, v/v) and then centrifuged at 
14,000 × g for 10 min at 4 °C to collect 200 μL supernatant for LC-MS analysis (below). Equal volumes from each 
of the A. baumannii strains samples were mixed for a quality control sample (QC). This pooled quality control 
sample was used to estimate a composite sample profile representing all the analytes that will be encountered 
during the LC-MS analysis62.
LC-MS analysis. Hydrophilic interaction liquid chromatography (HILIC)—high-resolution mass spec-
trometry (HRMS) was employed in this study. Samples were analysed on a Dionex high-performance liquid 
chromatography (HPLC) system (RSLCU3000, Thermo Fisher) using a ZIC-pHILIC column (5 μm, polymeric, 
150 × 4.6 mm; SeQuant, Merck) coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher) operated 
at 35000 resolution in both positive and negative electro-spray ionization (ESI) mode and a detection range of 85 
to 1,275 m/z. The LC solvent consisted of 20 mM ammonium carbonate (A) and acetonitrile (B) with a multi-step 
gradient system from 80% B to 50% B over 15 min, then to 5% B at 18 min, followed by wash with 5% B for 3 min, 
and 8 min re-equilibration with 80% B at a flow rate of 0.3 mL/min63. The run time was 32 min and the injection 
sample volume was 10 μL. All samples (3 biological replicates, each with 4 technical replicates) were randomized 
and analysed in a single LC-MS batch to reduce batch-to-batch variation. The chromatographic peaks, signal 
reproducibility and analyte stability were monitored by assessment of pooled quality control sample analysed 
periodically throughout the run, internal standards and total ion chromatograms for each sample. Mixtures of 
pure standards containing over 250 metabolites of different classes were analysed within the batch to aid in the 
identification of metabolites.
Data processing, bioinformatics and statistical analyses. Global metabolomics analyses were per-
formed using mzMatch64 and IDEOM (http:// mzmatch.sourceforge.net/ideom.php) free software65. Raw LC-MS 
data were converted to mzXML format and chromatogram peaks were detected using XCMS66 and saved in 
the peakML format. The program Mzmatch.R was used to align samples and filter peaks based on minimum 
detectable intensity (100000), reproducibility (relative standard deviation (RSD) for all replicates < 0.5) and peak 
shape (codadw > 0.8). Mzmatch.R was also used to retrieve LC-MS peak intensities for missing peaks and for 
the annotation of related peaks. Unwanted noise and artefact peaks were eliminated using IDEOM with default 
parameters. Metabolites were putatively identified by the exact mass within 2 ppm, after correction for loss or 
gain of a proton in negative and positive ESI mode, respectively. Retention time was employed to confirm the 
identification of each metabolite based on the available authentic standards. Putative identification of other 
metabolites was determined using exact mass and predicted retention time based on the Kyoto Encyclopedia of 
Genes and Genomes (KEGG), MetaCyc and LIPIDMAPS databases, with preference given to bacterial metab-
olites annotated in EcoCyc. Quantification of each metabolite was calculated using the raw peak height and is 
expressed relative to the average peak height for their paired susceptible strain. Univariate statistical analyses 
utilised a Welch’s T-test (α = 0.01) and multivariate analyses utilised the metabolomics R package. Metabolic 
pathway analyses were performed using the free web-based metabolomics tool Pathos (http://motif.gla.ac.uk/
Pathos/)67, BioCyc (http://biocyc.org/)68, and Visualization and Analysis of Networks containing Experimental 
Data (Vanted) software69.
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